Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor-positive Breast Cancer|Progesterone Receptor-positive Breast Cancer|Recurrent Breast Cancer|Stage IV Breast Cancer
Interventions: DRUG: anastrozole|DRUG: gefitinib|DRUG: fulvestrant|OTHER: laboratory biomarker analysis
Sponsor: National Cancer Institute (NCI)